Myriad Genetics Toekomstige groei

Future criteriumcontroles 0/6

Myriad Genetics zal naar verwachting groeien in winst en omzet met respectievelijk 53.8% en 5.4% per jaar. De winst per aandeel zal naar verwachting groeien met 70.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 4.9% zijn.

Belangrijke informatie

53.8%

Groei van de winst

70.4%

Groei van de winst per aandeel

Biotechs winstgroei	24.4%
Inkomstengroei	5.4%
Toekomstig rendement op eigen vermogen	4.9%
Dekking van analisten	Good
Laatst bijgewerkt	07 May 2025

Recente toekomstige groei-updates

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Feb 26

Recent updates

Myriad Genetics: Significantly Undervalued With Profitability In Sight

May 02

PATHOMIQ AI Partnership Will Expand Oncology And Women's Health

Mar 24 Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Mar 16

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Feb 26

Myriad Genetics: Navigating Through A Setback

Jan 16

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Jan 08

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Nov 02

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Nov 02

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18

Winst- en omzetgroeiprognoses

NasdaqGS:MYGN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2027	945	-1	33	48	10
12/31/2026	882	-57	23	48	16
12/31/2025	812	-63	26	32	12
3/31/2025	831	-101	-36	-6	N/A
12/31/2024	838	-127	-38	-9	N/A
9/30/2024	824	-116	-107	-70	N/A
6/30/2024	802	-155	-141	-93	N/A
3/31/2024	774	-235	-155	-96	N/A
12/31/2023	753	-263	-184	-111	N/A
9/30/2023	734	-274	-138	-63	N/A
6/30/2023	699	-248	-119	-44	N/A
3/31/2023	695	-146	-155	-93	N/A
12/31/2022	678	-112	-152	-106	N/A
9/30/2022	661	-77	-143	-108	N/A
6/30/2022	672	-18	-164	-145	N/A
3/31/2022	682	-8	-117	-100	N/A
12/31/2021	691	-27	1	19	N/A
9/30/2021	684	-57	-7	14	N/A
6/30/2021	662	-97	-26	-6	N/A
3/31/2021	566	-148	11	28	N/A
12/31/2020	557	-224	-40	-27	N/A
9/30/2020	598	-194	-25	-14	N/A
6/30/2020	639	-199	51	61	N/A
3/31/2020	761	-148	53	62	N/A
12/31/2019	813	-26	43	52	N/A
9/30/2019	835	-15	83	92	N/A
6/30/2019	851	5	75	84	N/A
3/31/2019	830	23	91	100	N/A
12/31/2018	796	26	N/A	105	N/A
9/30/2018	767	54	N/A	100	N/A
6/30/2018	744	133	N/A	116	N/A
3/31/2018	749	130	N/A	105	N/A
12/31/2017	763	126	N/A	134	N/A
9/30/2017	771	101	N/A	133	N/A
6/30/2017	729	17	N/A	106	N/A
3/31/2017	757	32	N/A	108	N/A
12/31/2016	751	63	N/A	113	N/A
9/30/2016	748	94	N/A	134	N/A
6/30/2016	741	117	N/A	166	N/A
3/31/2016	757	121	N/A	179	N/A
12/31/2015	747	108	N/A	163	N/A
9/30/2015	738	95	N/A	163	N/A
6/30/2015	723	80	N/A	141	N/A
3/31/2015	722	95	N/A	130	N/A
12/31/2014	725	110	N/A	112	N/A
9/30/2014	745	137	N/A	107	N/A
6/30/2014	778	176	N/A	190	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat MYGN de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat MYGN de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat MYGN de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van MYGN ( 5.4% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.3% per jaar).

Hoge groei-inkomsten: De omzet van MYGN ( 5.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen MYGN zal naar verwachting over 3 jaar laag zijn ( 4.9 %).

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/05/07 21:53
Aandelenkoers aan het einde van de dag	2025/05/07 00:00
Inkomsten	2025/03/31
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Myriad Genetics, Inc. wordt gevolgd door 41 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Jack Meehan	Barclays
Derek Taller	Benchmark Company
Michael Ryskin	BofA Global Research

Myriad Genetics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Myriad Genetics, Inc. Updates Earnings Guidance for the Year 2025

Price target decreased by 9.9% to US$16.01

Price target decreased by 7.3% to US$16.69

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Recent updates

Myriad Genetics, Inc. Announces Riskscore Study Published in JCO Precision Oncology

First quarter 2025 earnings released: US$0.001 loss per share (vs US$0.29 loss in 1Q 2024)

Myriad Genetics, Inc. Updates Earnings Guidance for the Year 2025

Myriad Genetics: Significantly Undervalued With Profitability In Sight

Myriad Genetics, Inc. to Report Q1, 2025 Results on May 06, 2025

Myriad Genetics Highlights MRD Clinical Validity Data At American Association for Cancer Research Annual Meeting

Myriad Genetics, Inc. Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations After GeneSight Testing

Price target decreased by 9.9% to US$16.01

Myriad Genetics, Inc., Annual General Meeting, Jun 05, 2025

Price target decreased by 7.3% to US$16.69

Myriad Genetics, Inc. Appoints Brian Donnelly as Chief Commercial Officer, Effective May 1, 2025

PATHOMIQ AI Partnership Will Expand Oncology And Women's Health

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Myriad Genetics, Inc. Announces Chief Executive Officer Changes

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Myriad Genetics, Inc. Announces Management Changes

Full year 2024 earnings released

Price target decreased by 8.6% to US$19.41

Myriad Genetics, Inc. to Report Q4, 2024 Results on Feb 24, 2025

Price target decreased by 8.0% to US$19.54

Consensus EPS estimates fall by 11%

Myriad Genetics: Navigating Through A Setback

Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Price target decreased by 10% to US$21.40

Myriad Genetics Elects Mark S. Davis as New Board Member

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 11% to US$26.69

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

CEO, President & Director notifies of intention to sell stock

Now 21% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold US$271k worth of stock

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Insider recently sold US$321k worth of stock

Consensus EPS estimates fall by 25%

Price target increased by 7.6% to US$27.82

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

New minor risk - Financial position

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024